硒充足地区硒补充与对照治疗Graves眼病的随机临床试验
这项随机、开放标签、多中心SeGOSS试验纳入84例硒充足地区的轻中度Graves眼病患者,比较硒联合维生素B复合物与对照治疗6个月的效果。主要结局6个月时GO-QOL总分变化两组无显著差异(差值0.9,95%CI -9.3至11.3,P=0.85)。3个月时硒组GO-QOL改善比例(78.4% vs 48.5%,P=0.01)和突眼改善率(49.5% vs 15.1%,P=0.01)较高,但6个月时未维持。
要点
- 6个月时硒组与对照组GO-QOL总分变化无显著差异(差值0.9,95%CI -9.3至11.3,P=0.85)。
- 3个月时硒组GO-QOL改善比例78.4% vs 对照组48.5%(差值0.30,95%CI 0.08-0.51,P=0.01)。
- 3个月时硒组突眼改善率49.5% vs 对照组15.1%(差值0.31,95%CI 0.11-0.51,P=0.01),6个月未维持。
核心结论
- 硒补充未改善硒充足地区轻中度Graves眼病患者6个月时的生活质量或临床指标。
- 3个月时观察到的一些潜在生活质量获益支持考虑进一步研究硒对该类患者的作用。
研究设计与样本
- SeGOSS试验为随机、开放标签、多中心研究,纳入84例轻中度Graves眼病患者,70例完成研究。
- 参与者基于Graves眼病诊断和充足硒水平入选,数据分析时间为2023年10月至2024年3月。
主要发现
- 6个月时GO-QOL总分变化硒组(平均[SD] 12.2[22.5])vs 对照组(平均[SD] 11.2[20.2]),差值0.9(95%CI -9.3至11.3,P=0.85)。
- 3个月时GO-QOL改善比例硒组78.4% vs 对照组48.5%,差值0.30(95%CI 0.08-0.51,P=0.01)。
- 3个月时突眼改善率硒组49.5% vs 对照组15.1%,差值0.31(95%CI 0.11-0.51,P=0.01),6个月时未维持。
关键数值与推荐
- 主要结局为6个月时GO-QOL评分改善。
- 次要结局包括3个月时GO-QOL评分变化、基于GO-QOL评分的改善比例、临床活动度评分和眼科检查(3个月和6个月),以及3个月和6个月甲状腺自身抗体变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Graves ophthalmopathy significantly diminishes patients' quality of life due to its immune-mediated inflammatory effects on the orbital tissues. Selenium, with its antioxidative properties, has shown potential for improving Graves ophthalmopathy progression and quality of life (QOL); however, its effectiveness in selenium-sufficient regions is not well established. OBJECTIVE: To determine whether selenium supplementation improves QOL in patients with mild to moderate Graves ophthalmopathy in selenium-sufficient regions. DESIGN, SETTING, AND PARTICIPANTS: The Efficacy of Selenium Supplementation for Mild-to-Moderate Graves' Ophthalmopathy in a Selenium-Sufficient Area (SeGOSS) trial was a randomized, open-label multicenter study. Eighty-four patients with mild to moderate Graves' ophthalmopathy were enrolled; 70 completed the study. Participants were selected based on Graves ophthalmopathy diagnosis and sufficient selenium levels. Data were analyzed from October 2023 to March 2024. INTERVENTIONS: Participants received selenium supplementation combined with vitamin B complex for 6 months. MAIN OUTCOMES AND MEASURES: The primary outcome was improvements in Graves ophthalmopathy QOL (GO-QOL) scores at 6 months. Secondary outcomes included changes in GO-QOL scores at 3 months, the proportion of patients showing improvement based on GO-QOL scores, clinical activity score, and ophthalmic examinations at 3 months and 6 months, and changes in thyroid autoantibodies at 3 months and 6 months. RESULTS: There was no improvement in changes in the total GO-QOL scores between the selenium group (31 female patients [83.8%] and 7 male patients [16.2%]; mean [SD] age, 40.8 [11.7] years) and control group (24 female patients [72.7%] and 9 male patients [27.3%]; mean [SD] age, 42.9 [14.2] years) for the primary outcome at 6 months (mean [SD], 12.2 [22.5] vs mean [SD], 11.2 [20.2]; difference, 0.9; 95% CI, -9.3 to 11.3; P = .85). However, at 3 months, a higher proportion of patients in the selenium group showed improved GO-QOL scores compared with the control group (78.4 vs 48.5%; difference, 0.30; 95% CI, 0.08-0.51; P = .01). The selenium group also had higher rates of improvement in proptosis reduction (49.5 vs 15.1%; difference, 0.31; 95% CI, 0.11-0.51; P = .01) at 3 months, though these effects were not sustained at 6 months. CONCLUSIONS AND RELEVANCE: These results suggest that selenium supplementation did not improve QOL or clinical parameters in patients with mild to moderate GO in selenium-sufficient regions at 6 months. Some potential QOL benefits noted at 3 months supports consideration of further investigation of selenium for patients seeking treatment for Graves ophthalmopathy . TRIAL REGISTRATION: Clinical Research Information Service Identifier KCT0004040.
引用
- Ahn HY, Lee MJ, Jung KY, et al. Selenium vs Control for Graves Ophthalmopathy in a Selenium-Sufficient Area: A Randomized Clinical Trial. JAMA Ophthalmol. 2025. PMID: 40014353. doi:10.1001/jamaophthalmol.2024.6337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。